Çocuklarda Subkutan İmmünglobülin Kullanımı

Abstract

İnsan plazma kaynaklı immünglobülinler başta primer immün yetersizlik hastalıkları olmak üzere pek çok hastalı- ğın tedavi seçenekleri arasında yer almaktadır. İmmünglobülin preparatları; intravenöz IV , subkutan SC ya da intramüsküler IM yolla verilebilir. Son yıllar- da subkutan immünglobülin SIG uygulaması, hasta konfo- runun daha yüksek, maliyetinin ve yan etki insidansının daha düşük olması nedeniyle tercih edilmektedir. Bu yazıda çocuk hastalarda SIG kullanımı ile ilgili güncel bilgiler özetlenmiştir

Keywords

• Subkutan immünglobülin,çocuk,tedavi

Subcutaneous Immunoglobulin Use in Children

Abstract

Human plasma derived immunoglobulin products have been considered among treatment options for many of the disor- ders, particularly primary immune deficiencies. Immunoglobulins can be administered either intravenous IV , subcutaneous SC or intramuscular IM route. In recent years, SCIG use has been preferred increasingly because of higher patient comfort, with decreased systemic side effects and costs. Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review

Keywords

• Subcutaneous immunoglobulin,children,treatment

References

1. Bruton oc. Agammaglobulinemia. Pediatrics 1952;9:722-8.
2. Jolles S. Subcutaneous and intramuscular immune globulin therapy. www.uptodate.com.
3. Janeway CA, Apt l, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953;66:200-2.
4. Gitlin D, Janeway CA. Agammaglobulinemia: conge- nital, acquired and transient forms. Prog Hematol 1956;1:318-56.
5. Hill lE, Mollison Pl. MRC working party on hypo- gammaglobulinemia, collection of cases and design of trial, Chap. II, Hypogammaglobulinemia in the UK. Her Majesty’s Stationery Office: London, 1971: pp. 4-8.
6. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779.
7. https://doi.org/10.1016/j.iac.2008.07.002
8. Stiehm ER. Adverse effects of human immunoglobu- lin therapy. Transfus Med Rev 2013;27:171.

9. https://doi.org/10.1016/j.tmrv.2013.05.004
10. Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy 2014;6:71-83.
11. https://doi.org/10.2217/imt.13.146
12. Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: A retrospective cohort study. PLoS One 2016;11: e0159993.
13. https://doi.org/10.1371/journal.pone.0159993
14. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglo- bulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011;16:92-7.
15. https://doi.org/10.1111/j.1529-8027.2011.00330.x
16. US Food and Drug Administration (FDA) approval: http://www.fda.gov/biologicsbloodvaccines/bloodblo- odproducts/approvedproducts/licensedproductsblas/ fractionatedplasmaproducts/ucm414117.htm (Accessed on September 19, 2014).
17. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734.
18. https://doi.org/10.1007/s10875-010-9423-4
19. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunog- lobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265.
20. https://doi.org/10.1007/s10875-006-9021-7
21. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs 2007;21:105.
22. https://doi.org/10.2165/00063030-200721020-00005
23. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a revi- ew of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117:S525.
24. https://doi.org/10.1016/j.jaci.2006.01.015
25. Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28:803.
26. https://doi.org/10.1016/j.iac.2008.06.006
27. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in pati- ents with primary immunodeficiencies. Clin Immunol 2011;139:133.
28. https://doi.org/10.1016/j.clim.2011.01.006
29. Waniewski J, Gardulf A, Hammarström l. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunode- ficiency. J Clin Immunol 1994;14:90.
30. https://doi.org/10.1007/BF01541341
31. Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in pati- ents with primary immunodeficiencies. Clin Immunol 2011;139:133.
32. https://doi.org/10.1016/j.clim.2011.01.006
33. Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglo- bulin for primary immunodeficiency in the United States. J Clin Immunol 2013;33:49.
34. https://doi.org/10.1007/s10875-012-9776-y
35. Kobrynski l. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodefici- ency diseases. Biologics 2012;6:277-87.
36. https://doi.org/10.2147/BTT.S25188
37. Jolles S, Orange JS, Gardulf A, et al. Current treat- ment options with immunoglobulin G for the individu- alization of care in patients with primary immunodefi- ciency disease. Clin Exp Immunol 2015;179:146.
38. https://doi.org/10.1111/cei.12485
39. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122:210.
40. https://doi.org/10.1016/j.jaci.2008.04.044
41. Gardulf A, nicolay U, Asensio O, et al. Rapid subcu- taneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies- -a prospective, multi-national study. J Clin Immunol 2006;26:177.
42. https://doi.org/10.1007/s10875-006-9002-x
43. Markvardsen lH, Christiansen I, Andersen H, Jakobsen J. Headache and nausea after treatment with high-dose subcutaneous versus intravenous immuno- globulin. Basic Clin Pharmacol Toxicol 2015;117:409- 12.
44. https://doi.org/10.1111/bcpt.12428
45. Epstein JS, Zoon KC. Dear doctor letter - important drug warning: immune globulin intravenous (human). FDA Med Watch. US Food and Drug Administration; 1998.
46. Pierce lR, Jain n. Risks associated with the use of intravenous immunoglobulin. Transfusion Med Rev 2003;17:241-51.
47. https://doi.org/10.1016/S0887-7963(03)00038-5
48. Fasth A, nystrom J. Safety and efficacy of subcutane- ous human immunoglobulin in children with primary immunodeficiency. Acta Paediatrica 2007;96:1474-8.
49. https://doi.org/10.1111/j.1651-2227.2007.00485.x
50. Sundin U, nava S, Hammarstrom l. Induction of unresponsiveness against IgA in IgA- deficient patients on subcutaneous immunoglobulin infusion therapy. Clin Exp Immunol 1998;112:341-6.
51. https://doi.org/10.1046/j.1365-2249.1998.00571.x
52. Karakoç Aydıner E, Kıykım A, Barıs S, Özen A, Barlan I. Use of subcutaneous immunoglobulin in primary immune deficiencies. Turk Pediatri Ars 2016;51:8-14.
53. https://doi.org/10.5152/TurkPediatriArs.2016.3058
54. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei n. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody defi- ciencies: systematic review and meta-analysis. J Clin Immunol 2012;32:1180-92.
55. https://doi.org/10.1007/s10875-012-9720-1
56. Bonilla FA, Duff C. Subcutaneous Immunoglobulin Replacement. Immune Deficiency Foundation: Clinical Focus 2015;16:1-16.